Advertisement
Research Article Free access | 10.1172/JCI119404
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Engleman, V. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Nickols, G. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Ross, F. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Horton, M. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Griggs, D. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Settle, S. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Ruminski, P. in: JCI | PubMed | Google Scholar
Searle Corporation, St. Louis, Missouri 63167, USA.
Find articles by Teitelbaum, S. in: JCI | PubMed | Google Scholar
Published May 1, 1997 - More info
Osteoclastic bone degradation requires intimacy between the matrix and the resorptive cell. While the precise role the integrin alpha(v)beta3 plays in the process is not yet understood, occupancy of the heterodimer by soluble ligand or by blocking antibody effectively inhibits bone resorption in vitro and in vivo, suggesting that alpha(v)beta3 blockade may prevent postmenopausal osteoporosis. Thus, we identified a synthetic chemical peptide mimetic, beta-[2-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-1-+ ++oxoethyl]amino-3-pyridinepropanoic acid, bistrifluoroacetate (SC56631) based upon the alpha(v)beta3 ligand, Arg-Gly-Asp (RGD), which recognizes the isolated integrin, and its relative, alpha(v)beta5, as effectively as does the natural peptide. The mimetic dampens osteoclastic bone resorption in vitro and in vivo. Most importantly, intravenous administration of the mimetic prevents the 55% loss of trabecular bone sustained by rats within 6 wk of oophorectomy. Histological examination of bones taken from SC56631-treated, oophorectomized animals also demonstrates the compound's bone sparing properties and its capacity to decrease osteoclast number. Thus, an RGD mimetic prevents the rapid bone loss that accompanies estrogen withdrawal.